WASHINGTON, DC - Energy and Commerce Committee Chairman Greg Walden (R-OR) today shared an important message regarding H.R. 2430, the FDA Reauthorization Act (FDARA) of 2017, legislation to reauthorize FDA’s critically important user fee programs. Watch the video below to learn more about why this bill is a win for patients, drug and device manufacturers, and the millions of Americans who work in the health care industry.
The House will consider H.R. 2430 this week.
